eXoZymes and MDB Capital Announce Leadership Transition at eXoZymes Inc.
eXoZymes (NASDAQ: EXOZ) announced significant leadership changes in its board of directors. Mo Hayat has stepped down as Chairman and President to focus on new ventures at MDB Capital. Edgardo Rayo, who initially discovered the scientific co-founders at UCLA, joins the board representing MDB Capital. Christopher Marlett, current board member and CEO of MDB Capital, will become Chairman.
Michael Heltzen, CEO of eXoZymes, will now also serve as President. The transition follows the company's recent rebranding from Invizyne Technologies and ticker change to 'EXOZ' on February 12, 2025. eXoZymes specializes in AI-engineered enzymes that transform sustainable feedstock into essential chemicals, medicines, and biofuels.
eXoZymes (NASDAQ: EXOZ) ha annunciato importanti cambiamenti nella leadership del suo consiglio di amministrazione. Mo Hayat si è dimesso da Presidente e Amministratore Delegato per concentrarsi su nuove iniziative presso MDB Capital. Edgardo Rayo, che ha scoperto inizialmente i co-fondatori scientifici presso UCLA, entra a far parte del consiglio in rappresentanza di MDB Capital. Christopher Marlett, attuale membro del consiglio e CEO di MDB Capital, diventerà Presidente.
Michael Heltzen, CEO di eXoZymes, assumerà ora anche il ruolo di Presidente. La transizione segue il recente rebranding dell'azienda da Invizyne Technologies e il cambiamento del ticker in 'EXOZ' il 12 febbraio 2025. eXoZymes si specializza in enzimi progettati con intelligenza artificiale che trasformano materie prime sostenibili in sostanze chimiche essenziali, medicinali e biocarburanti.
eXoZymes (NASDAQ: EXOZ) anunció cambios significativos en el liderazgo de su junta directiva. Mo Hayat ha renunciado como Presidente y CEO para enfocarse en nuevas iniciativas en MDB Capital. Edgardo Rayo, quien descubrió inicialmente a los cofundadores científicos en UCLA, se une a la junta representando a MDB Capital. Christopher Marlett, actual miembro de la junta y CEO de MDB Capital, se convertirá en Presidente.
Michael Heltzen, CEO de eXoZymes, ahora también asumirá el cargo de Presidente. La transición sigue al reciente cambio de marca de la empresa de Invizyne Technologies y al cambio de ticker a 'EXOZ' el 12 de febrero de 2025. eXoZymes se especializa en enzimas diseñadas con inteligencia artificial que transforman materias primas sostenibles en productos químicos esenciales, medicamentos y biocombustibles.
eXoZymes (NASDAQ: EXOZ)는 이사회에서 중요한 리더십 변화를 발표했습니다. Mo Hayat는 MDB Capital에서 새로운 사업에 집중하기 위해 회장직과 CEO직에서 물러났습니다. UCLA에서 과학 공동 창립자를 처음 발견한 Edgardo Rayo가 MDB Capital을 대표하여 이사회에 합류합니다. 현재 이사회 멤버이자 MDB Capital의 CEO인 Christopher Marlett가 회장이 됩니다.
eXoZymes의 CEO인 Michael Heltzen은 이제 회장직도 맡게 됩니다. 이 전환은 Invizyne Technologies에서의 최근 브랜드 변경과 2025년 2월 12일 'EXOZ'로의 티커 변경에 이어 이루어졌습니다. eXoZymes는 지속 가능한 원료를 필수 화학물질, 의약품 및 바이오 연료로 변환하는 AI 엔지니어링 효소를 전문으로 하고 있습니다.
eXoZymes (NASDAQ: EXOZ) a annoncé des changements significatifs dans la direction de son conseil d'administration. Mo Hayat a démissionné de son poste de Président et de PDG pour se concentrer sur de nouvelles initiatives chez MDB Capital. Edgardo Rayo, qui a initialement découvert les co-fondateurs scientifiques à UCLA, rejoint le conseil en représentant MDB Capital. Christopher Marlett, membre actuel du conseil et PDG de MDB Capital, deviendra Président.
Michael Heltzen, PDG d'eXoZymes, exercera désormais également la fonction de Président. La transition fait suite au récent changement de marque de l'entreprise d'Invizyne Technologies et au changement de ticker en 'EXOZ' le 12 février 2025. eXoZymes se spécialise dans les enzymes conçues par intelligence artificielle qui transforment des matières premières durables en produits chimiques essentiels, médicaments et biocarburants.
eXoZymes (NASDAQ: EXOZ) gab bedeutende Veränderungen in der Führung seines Vorstands bekannt. Mo Hayat ist als Vorsitzender und CEO zurückgetreten, um sich auf neue Unternehmungen bei MDB Capital zu konzentrieren. Edgardo Rayo, der die wissenschaftlichen Mitbegründer an der UCLA erstmals entdeckte, tritt dem Vorstand als Vertreter von MDB Capital bei. Christopher Marlett, aktuelles Vorstandsmitglied und CEO von MDB Capital, wird Vorsitzender.
Michael Heltzen, CEO von eXoZymes, wird nun auch als Präsident fungieren. Der Übergang folgt der kürzlichen Umbenennung des Unternehmens von Invizyne Technologies und der Änderung des Tickers zu 'EXOZ' am 12. Februar 2025. eXoZymes spezialisiert sich auf KI-entwickelte Enzyme, die nachhaltige Rohstoffe in essentielle Chemikalien, Medikamente und Biokraftstoffe umwandeln.
- Appointment of Edgardo Rayo brings valuable historical knowledge of company's founding technology
- Consolidation of leadership under CEO Michael Heltzen who adds President role
- Continued support from MDB Capital through new Chairman Christopher Marlett
- Loss of experienced Chairman and President Mo Hayat
- Potential disruption in leadership continuity during transition period
Monrovia, CA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- eXoZymes Inc. (NASDAQ: EXOZ, formerly Invizyne Technologies) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential chemicals, medicines, and biofuels - and MDB Capital Holdings (NASDAQ: MDBH) - a premier venture platform for breakthrough technology companies - today announced key leadership changes within the eXoZymes board of directors.
Mo Hayat has transitioned out of his roles as Chairman of the Board and President of eXoZymes, to focus on new MDB Capital ventures. Edgardo Rayo will join the board on behalf of MDB Capital, making it a full circle moment, as he was the MDB Capital team member who discovered the team of scientific co-founders at UCLA and recognized the transformative potential of the science that ultimately evolved into eXoZymes.
Christopher Marlett, CEO of MDB Capital and a current board member of eXoZymes, will assume the role of Chairman to ensure the help and support that MDB Capital will continue to provide eXoZymes.
Michael Heltzen, CEO of eXoZymes, expressed his gratitude for Mo Hayat’s contributions, “Mo has been instrumental in guiding eXoZymes through critical milestones, including my transition to CEO and our successful public offering. On behalf of the entire team, I extend my deepest thanks to Mo for his dedication and getting the company off to a great venture journey.” Henceforth Michael Heltzen will serve as the President of eXoZymes Inc.
Christopher Marlett highlighted Mo Hayat’s ongoing role at MDB Capital, “Mo’s expertise in developing new companies has been invaluable to MDB’s mission of licensing transformative technologies and building them into successful enterprises. We look forward to Mo focusing his efforts toward launching new ventures under the MDB umbrella.”
The leadership transition comes shortly after eXoZymes’ corporate rebranding from Invizyne Technologies and its ticker symbol change to “EXOZ” on February 12, 2025. These changes reflect the company’s commitment to advancing its innovative biomanufacturing platform.
About eXoZymes Inc.
Founded in 2019, the company has developed a platform that - as a historic first - offers the tools and insight to control and optimize nature’s own processes to produce chemical compounds, enabling the company’s partners to replace traditional chemical production methods with a new sustainable, scalable, and eco-friendly alternative: Exozymes.
Exozymes are advanced enzymes enhanced with AI and bioengineering to thrive in a bioreactor outside of living cells. Exozymes can replace toxic petrochemical processes and inefficient biochemical extraction with sustainable and scalable biosolutions, that transform biomass into essential chemicals, medicines, and biofuels.
By freeing enzyme-driven chemical reactions from the limitations imposed by cells, exozyme biosolutions eliminate the scaling bottleneck that has hampered commercial success in the synthetic biology (SynBio) space, making exozymes the logical successor to most SynBio projects. After SynBio, this pioneering technology enables entering the exozymes era of biotechnology.
Inspired by insights from four recent Nobel Prizes in Chemistry, this technological platform ushers in a paradigm shift in chemical production by introducing scalable and sustainable exozyme biosolutions.
While the company, eXoZymes Inc., has introduced “exozymes” (エキソザイム in Japanese katakana) as a scientific concept, they are not trademarking the concept, as they view it as a new nomenclature for wide adoption.
Learn more on exozymes.com.
Investor relations contact
Email: ir@exozymes.com
eXoZymes media contact
Lasse Görlitz, VP of Communications
(858) 319-7135
press@exozymes.com
MDB Capital Holdings media contact
Email: media@mdb.com
FAQ
What leadership changes were announced at eXoZymes (EXOZ) on February 21, 2025?
Why did Mo Hayat leave his positions at eXoZymes (EXOZ)?
When did eXoZymes change its ticker symbol to EXOZ?
Who is the new Chairman and President of eXoZymes (EXOZ)?
What is the connection between Edgardo Rayo and eXoZymes (EXOZ)?
